Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Olaparib Withstands the Test of Time With Long-Term Data Supporting Its Role in Ovarian Cancer Treatment

October 13th 2025

Kevin Elias, MD, discusses the role of olaparib in the management of ovarian cancer.

Abemaciclib Displays Efficacy, Tolerability in HIV-Associated and HIV-Negative Kaposi Sarcoma

October 13th 2025

Abemaciclib was safe and active for the treatment of patients with HIV-associated and -negative Kaposi sarcoma.

Subcutaneous Pembrolizumab Shows Possibility of Providing Effective and Convenient Treatment in Oncology

October 12th 2025

J. Thaddeus Beck, MD, FACP, discusses the FDA approval of subcutaneous pembrolizumab in solid tumors.

FDA Grants Orphan Drug Designation to Cintredekin Besudotox in Glioblastoma

October 10th 2025

The regulatory agency has granted orphan drug designation to cintredekin besudotox for the treatment of patients with glioblastoma.

OST-HER2 Displays Potential OS Benefit in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

October 10th 2025

OST-HER2 produced a potential overall survival benefit at 2 years in recurrent, fully resected, pulmonary metastatic osteosarcoma.

ESMO 2025 Will See Novel Agents Emerge and Standard Strategies Shift in GI Oncology

October 9th 2025

Ahead of the 2025 ESMO Congress, GI cancer experts share the gastric cancer and CRC research they’re most looking forward to seeing at the meeting.

Personalization Drives Next Wave of Metastatic Castration-Sensitive Prostate Cancer Treatment

October 7th 2025

A panel of experts discusses the effort to personalize treatment approaches in metastatic castration-sensitive prostate cancer.

NICE Recommends First-Line Lorlatinib for Newly Diagnosed ALK+ NSCLC

October 7th 2025

Lorlatinib has received NICE’s recommendation for untreated advanced non–small cell lung cancer.

Pembrolizumab Plus Chemotherapy Shows Preliminary Activity in Advanced Penile Cancer

October 2nd 2025

The addition of the PD-1 inhibitor to platinum-based chemotherapy demonstrated proof of concept for the use of chemoimmunotherapy in patients with PSCC.

AMXT 1501 Plus Difluoromethylornithine Nets FDA Orphan Drug Designation in Neuroblastoma

October 2nd 2025

AMXT 1501 plus difluoromethylornithine has received orphan drug designation from the FDA in patients with neuroblastoma.

Inside the Most Anticipated Lung Cancer Abstracts: What to Expect From ESMO 2025

October 2nd 2025

Ahead of the 2025 ESMO Congress, OncLive spoke with experts in lung cancer care to preview the most anticipated meeting abstracts.

Dual-Binding XmAb30819 Shows Strong Specificity in ENPP3-Positive RCC

October 1st 2025

ENPP3 offers a potentially attractive treatment target in patients with clear cell RCC.

How AI-Driven Platforms Can Transform Clinical Trial Efficiency in Cancer Care

October 1st 2025

Katie Goodman, RN, BSN, discusses the ways in which artificial intelligence can help speed up the pace of clinical trial accrual

Dr Dietrich on the Limitations of Chemotherapy in Pancreatic Cancer

September 30th 2025

Martin F. Dietrich, MD, PhD, discusses the limitations of frontline chemotherapy in advanced/metastatic pancreatic cancer.

Predictors of cGVHD Outcomes Remain Elusive in Pediatric Hematologic Malignancies

September 29th 2025

Acute GVHD was shown to be a risk factor for chronic GVHD, but factors such as organ involvement showed no correlation with long-term outcomes.

Recognizing the Rapidly Changing World of Surgical Oncology

September 29th 2025

Maurie Markman, MD, discusses the evolution of surgical oncology, from radical resections to multidisciplinary, minimally invasive, and neoadjuvant approaches.

From Overload to Insight: Why AI Is Becoming an Essential Partner in Oncology

September 28th 2025

Brian P. Mulherin, MD, discusses how artificial intelligence is helping shape smarter cancer care.

Simplifying Care Navigation in Oncology: A Painless Path to Better Support

September 28th 2025

Lalan Wilfong, MD, discusses the patient- and provider-facing implications that may result from renewed focus on improving care navigation in oncology.

Flora Charts the Future of AI in Community Cancer Care

September 27th 2025

Doug Flora, MD, FACC, LSSBB, explains how AI is transforming cancer care, urging oncologists to engage and guide its responsible use.

Sunvozertinib Approval Fills Treatment Gap in Pretreated EGFR Exon 20–Mutant NSCLC

September 26th 2025

Lyudmila A. Bazhenova, MD, discusses the FDA approval of sunvozertinib (Zegfrovy) in patients with EGFR exon 20–mutant non–small cell lung cancer.